Market Overview

CytRx Receives FDA Approval To Extend Aldoxorubicin Dosing Cycles Until Disease Progression In Upcoming Pivotal, Global Phase 3 Trial For Soft Tissue Sarcomas

Share:

Posted-In: News FDA

 

Related Articles (CYTR)